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Abstract
Working Hypothesis
The p53 transcription factor, encoded by the human gene TP53, is the most commonly mutated 
gene in human cancers. Once the TP53 gene is mutated, p53 proteins not only lose their tumor 
suppression abilities but can also contribute to tumor growth. One-way mutant p53 can do this is 
by increasing iron uptake and availability by altering the regulation of iron-sulfur (Fe-S) cluster 
containing proteins. Understanding such alterations are important because Fe-S cluster proteins 
play a role in both energy metabolism and DNA repair enzymes, which can suppress the 
progression and expansion of cancerous tumors. This study’s main focus was to examine how TP53 
mutation status influences Fe-S cluster protein regulation, and subsequently iron homeostasis in 
tumor cells.  First, we assessed the activity of the Fe-S containing enzymes cytosolic and 
mitochondrial aconitase in cell lines expressing a variety of TP53 mutations. Specifically, we will use 
cell lines that express the six most commonly observed TP53 mutations, which represent nearly 
25% of all TP53 mutations in human cancers. We found that while aconitase activity decreased as 
expected following the removal of iron in cells expressing wild-type (WT) TP53, the influence of 
iron chelation on aconitase activity in cells expressing mutant TP53 varied depending on mutation 
type. This data strongly suggests that TP53 mutations significantly influence how the activity of Fe-
S cluster enzymes is regulated. Thus, our ongoing studies are focused on investigating how TP53 
mutation status influences the regulation of genes involved with Fe-S cluster biogenesis and 
consequently, Fe-S cluster containing protein activity.
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by iron availability in WT and mutant TP53 expressing cells
Experimental Approach
Figure 1. Working model of mutant TP53 dependent alterations in cellular iron 
homeostasis. (A) In response to increased iron availability, wild-type TP53 induces 
ISCU and FDXR expression, and promotes Fe-S cluster assembly and the reduction of 
iron regulatory protein (IRP) mRNA binding activity. Decreased IRP mRNA binding 
activity promotes sequestration of excess iron into ferritin and decreases transferrin 
receptor (TFRC)-mediated iron uptake. (B) In cells expressing mutant TP53, IRP RNA 
binding activity is unaffected by excess iron, and the labile iron pool, and thus ROS 
production is significantly increased.
Results
24-hour treatment with DFO or hemin induces iron deficiency and iron 
overload, respectively
Figure 5. The influence of iron chelation on Fe-S cluster containing enzyme activity in WT and mutant 
TP53 expressing cells. Cells were treated with 100 𝜇𝜇M DFO and untreated (control) for 24 hours.  As 
expected, (A) cytosolic aconitase was significantly decreased in cells expressing WT TP53, and the cell 
line expressing the R248 TP53 mutation type. However, cytosolic aconitase activity in the R175H mutant 
TP53 expressing cell line actually increased in response to iron chelation. Similarly, (B) mitochondrial 
aconitase activity was reduced in cells expressing WT TP53 but was unaffected in any of the mutant 
TP53 expressing cell lines examined. *Denotes statistical difference from respective controls, p < 0.05.
Figure 3. Experimental workflow. Each of the cell lines shown in Figure 2 were plated at equal cell 
densities and left untreated (control) or were treated with 50 µM or 100 µM of the iron chelator, 
desferrioxamine (DFO), or 40 µM of the heme iron supplement, hemin, for 24 hours. Cytosolic and 
mitochondrial subcellular fractionation was then performed by differential centrifugation, and cytosolic 
and mitochondrial aconitase activities were measured using an Aconitase Activity Assay kit 
(MilliporeSigma). This assay determines aconitase activity by using a coupled reaction in which citrate is 
converted to isocitrate by aconitase.  
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Figure 4. The influence of iron chelation and supplemental iron on TFRC expression in WT and mutant 
TP53 expressing cells. TFRC expression was assessed by western blot in (A) WT TP53 expressing SW48 
cells and (B) R175H mutant TP53 expressing AU565 cells following treatment with 50 µM DFO or 40 µM 
hemin for 24 hours. (C and D). Relative expression levels were quantitated following normalization to 
anti-gamma tubulin (TUBG1) as the loading control *Denotes statistical difference from respective 
controls, p < 0.05.
Figure 2. Panel of cell lines representing the six TP53 “hotspot” mutation sites. (A) 
Frequency of TP53 mutation types for all human cancers. (B) For this work we 
obtained a panel of human cancer cell lines that endogenously express either WT 
TP53, or one of the six most commonly observed TP53 mutation types in human 
cancers and cultured under standard conditions. Part A of this figure was adapted 
from: William A. Freed-Pastor, and Carol Prives Genes Dev. 2012;26:1268-1286
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Figure 6. Workflow for next steps of the project. All cell lines will be treated as 
previously described. RNA will then be isolated and used to synthesize cDNA for 
qPCR analysis to examine the expression of genes controlling Fe-S cluster 
biogenesis. 
Such studies are important because a mechanistic understanding as to how 
homeostatic control of iron metabolism is maintained in cancer cells expressing 
distinct TP53 mutations could lead to improved iron-targeted chemotherapy 
strategies
• Both WT and mutant TP53 expressing cells respond to iron chelation and iron 
supplementation by increasing or decreasing the expression of the iron 
uptake protein TFRC.
• In response to reduced iron availability, cells expressing WT TP53 respond by 
reducing the enzymatic activity of Fe-S containing proteins.
• Most mutant TP53 expressing cell types examined did not appropriately 
repress the enzymatic activity of Fe-S containing proteins in response to low 
iron availability.
• Incongruous use of iron in response to alterations in iron availability may 
represent an exploitable weakness for targeting mutant TP53 expressing 
cancers.
